natgillin/translations-raw huggingface dataset:
Store outside of the refrigerator at or below 30°C for a period of not more than 3 months until expiry.
Shranjujte izven hladilnika pri temperaturi do 30 °C ne več kot 3 mesece in do izteka roka uporabnosti.
Store outside of the refrigerator at or below 30°C for a period of not more than 3 months until expiry.
Shranjujte zunaj hladilnika pri temperaturi do 30 °C do največ 3 mesece in do izteka roka uporabnosti.
Store outside of the refrigerator at or below 30C for a period of not more than 3 months until expiry.
Shranjujte izven hladilnika pri temperaturi do 30 C ne več kot 3 mesece in do izteka roka uporabnosti.
Store partially used tablets in the original blister.
Delno uporabljene tablete shranjujte v originalnem pretisnem omotu.
Store partially used tablets in the original bottle.
Delno uporabljene tablete shranjujte v originalnem vsebniku.
Store powder and solvent below 25°C.
Prašek in topilo shranjujte pri temperaturi do 25 °C.
Store powder and solvent below 25C.
Prašek in topilo shranjujte pri temperaturi do 25 °C.
Store powder and solvent protected from light.
Prašek in topilo shranjujte zaščiteno pred svetlobo.
Store pre-filled, capped syringes of diluted IL-2 dispensed by the pharmacist in the refrigerator (at 2°C – 8°C) until use.
Prednapolnjene brizge razredčenega IL-2 s pokrovčkom, ki jih je pripravil farmacevt, do uporabe shranjujte v hladilniku (2°C – 8°C).
Store refrigerated (2 C – 8 C).
Shranjujte v hladilniku (2 C–8 C).
Store refrigerated (2°C to +8°C).
Shranjujte in prevažajte v hladilniku (2 °C do +8 °C).
Store refrigerated (2C to 8C).
Shranjujte v hladilniku (2 C do 8 C).
Store refrigerated at 2C to 8C.
Shranjujte v hladilniku pri temperaturi od 2 C do 8 C.
Store separately from the fibrinogen and thrombin, at room temperature.
Shranjujte pri sobni temperaturi ločeno od raztopin fibrinogena in trombina.
Store the administration system in a refrigerator (2°C - 8°C).
Aplikacijski sistem shranjujte v hladilniku (2 °C do 8 °C).
Store the Avonex pen in the original box to protect from light.
Napolnjen injekcijski peresnik Avonex Pen shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store the bag in the insulated container to maintain the correct storage temperature (2°C–8°C) until infusion.
Vrečko shranjujte v izoliranem vsebniku za ohranjanje pravilne temperature shranjevanja (2 °C–8 °C) do infundiranja.
Store the bag in the insulated container to maintain the correct storage temperature (2°C–8°C) until infusion.
Vrečko shranjujte v izoliranem vsebniku, da ohranite pravilno temperaturo shranjevanja (2 °C–8 °C) do indunfiranja.
Store the bag in the insulated container to maintain the correct storage temperature (2°C–8°C) until infusion.
Vrečko shranjujte v izoliranem vsebniku, da ohranite pravilno temperaturo shranjevanja (2 °C–8 °C) do infundiranja.
Store the bag in the insulated container to maintain the correct storage temperature (2°C–8°C) until infusion.
Vrečko shranjujte v izoliranem vsebniku, da ohranjate pravilno temperaturo shranjevanja (2 °C–8 °C) do infundiranja.
Store the bottle and the syringe together in the carton box between each use.
Po vsaki uporabi shranite steklenico in brizgo skupaj v škatlo.
Store the bottle and the syringe together in the carton until next use in a safe place where your child can’t see or reach it.
Steklenico in brizgo skupaj shranite do naslednje uporabe v škatlo in na varno mesto, kjer je otrok ne more videti ali doseči.
Store the bottle upright.
Steklenico shranjujte v pokončnem položaju.
Store the broached vial with the adaptor in an upright position.
Prebodeno vialo z adapterjem shranjujte v pokončnem položaju.
Store the broached vial with the adaptor in an upright position.
Shranjujte prebodeno vialo z adapterjem v pokončnem položaju.
Store the capsules in the original package in order to protect from moisture and do not remove until immediately before use.
Kapsule shranjujte v originalni ovojnini, da jih zaščitite pred vlago, in jih vzemite iz ovojnine šele tik pred uporabo.
Store the complete pack in the refrigerator at 2°C to 8°C and away from direct sunlight.
Celotno pakiranje shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C ter zaščiteno pred neposredno sončno svetlobo.
Store the diluted infusion solution between 2 C and 8 C and use within 24 hours.
Razredčeno raztopino za infundiranje shranjujte pri temperaturi od 2 C do 8 C in jo uporabite v 24 urah.
Store the FORSTEO with the white cap on.
Injekcijski peresnik FORSTEO shranjujte s pritrjenim belim pokrovom.
Store the medicine in a refrigerator at a temperature of between 2°C and 8°C.
Zdravilo hranite v hladilniku pri temperaturi med 2°C in 8°C.
Store the oral dosing syringe and the medicine cup for next use.
Peroralno odmerno brizgo in lonček za zdravilo je treba shraniti za naslednjo uporabo.
Store the oral dosing syringe and the medicine cup for next use.
Peroralno odmerno brizgo in lonček za zdravilo shranite za naslednjo uporabo.
Store the oral syringe with the bottle in the outer carton between each use.
Steklenico in brizgo shranite v škatli do naslednje uporabe.
Store the package at room temperature (up to 27°C).
Pakiranje shranjujte na sobni temperaturi (do 27 °C).
Store the PecFent bottle in the child resistant container at all times, even when finished.
Steklenico z zdravilom PecFent vedno shranjujte v vsebniku z zaporko, varno za otroke, tudi če je že prazna.
Store the pen in its original packaging in a safe place.
Injekcijski peresnik shranjujte v originalni ovojnini na varnem mestu.
Store the pen in the original package in order to protect from light.
Zdravilo Trulicity shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store the pen sealed in its box to protect from light.
Injekcijski peresnik shranjujte v originalno zaprti škatli za zagotovitev zaščite pred svetlobo.
Store the Pen you are currently using at room temperature (up to 30°C) and away from heat and light.
Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (do 30 °C) in ga zaščitite pred toploto in svetlobo.
Store the pen you are currently using at room temperature [below 30 ° C] and away from heat and light.
Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi [do 30 °C] in zaščitenega pred toploto in svetlobo.
Store the Pen you are currently using at room temperature up to 30°C and away from heat and light.
Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi do 30 °C in ga zaščitite pred vročino in svetlobo.
Store the pens in the original package in order to protect from light.
Injekcijske peresnike shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store the pipettes in the original package in order to protect from moisture and light.
Shranjujte merilne kapalke v originalni ovojnini, da so zaščitene pred vlago in svetlobo.
Store the pipettes in the original package in order to protect from moisture and light.
Shranjujte merilno kapalko v originalni ovojnini, da je zaščitena pred vlago in svetlobo.
Store the Podhaler device in its tightly closed case when not in use.
Kadar inhalatorja Podhaler ne uporabljate, ga shranjujte v etuiju, ki se mu natančno prilega.
Store the pre-filled pen
Shranite napolnjen injekcijski peresnik
Store the pre-filled syringe in the original package in order to protect from light.
Napolnjeno injekcijsko brizgo shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store the radiolabelled product in a shield.
Radiooznačeno zdravilo shranite v ščitu.
Store the reconstituted solution for injection upright at 15 C – 25 C and use within 5 hours of preparation.
Rekonstituirano raztopino shranjujte v pokončnem položaju pri 15˚C-25˚C in jo uporabite znotraj 5 ur po pripravi.
Store the syringe in the original package in order to protect from light.
Zdravilo Trulicity shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store the syringe sealed in its box to protect from light.
Injekcijsko brizgo shranjujte v originalno zaprti škatli za zagotovitev zaščite pred svetlobo.
Store the vaccine in liquid nitrogen.
Cepivo shranjujte v tekočem dušiku.
Store the vial of powder in the refrigerator between 2°C to 8°C.
Vialo s praškom shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C.
Store the vials in the original package in order to protect from light.
Viale shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Store this medicine in the original package in order to protect from light and moisture.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo in vlago.
Store this medicine sealed in its outer box to protect it from light.
Za zagotovitev zaščite pred svetlobo shranjujte to zdravilo originalno zaprto v zunanji škatli.
Store unused pens in the refrigerator at 2 ° C to 8 ° C.
Neuporabljene peresnike shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C.
Store unused Pens in the refrigerator at 2°C to 8°C.
Neuporabljene peresnike shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C.
Store unused pens in the refrigerator at 2°C to 8°C. For detailed storage conditions see separate package leaflet for Praluent.
Neuporabljene peresnike shranjujte v hladilniku pri temperaturi od 2 do 8 °C. Za podrobne pogoje shranjevanja glejte ločeno navodilo za uporabo zdravila Praluent.
Store unused syringes in the refrigerator at 2°C to 8°C. For detailed storage conditions see separate package leaflet for Praluent.
Neuporabljene brizge shranjujte v hladilniku pri temperaturi od 2 do 8 °C. Za podrobne pogoje shranjevanja glejte ločeno navodilo za uporabo zdravila Praluent.
Store unused syringes in the refrigerator in the original carton.
Neuporabljene napolnjene injekcijske brizge z varovalom za iglo morate vedno shranjevati v hladilniku v originalni ovojnini.
Store upright in a refrigerator (2 °C – 8 °C).
Shranjujte pokončno v hladilniku (2 °C - 8 °C).
Store upright in a refrigerator (2 °C – 8 °C).
Shranjujte pokončno v hladilniku (2°C - 8°C).
Store upright in a refrigerator (2oC - 8ºC).
Shranjujte v hladilniku (2 °C - 8 °C) v pokončnem položaju.
Store upright in a refrigerator.
Shranjujte v pokončnem položaju v hladilniku .
Store upright.
Shranjujte pokončno.
Store upright.
Shranjujte v pokončnem položaju.
Store vial upright with the adaptor attached.
Vialo z nameščenim adapterjem shranite v pokončnem položaju.
Store vials in a refrigerator (2°C–8°C).
Viale shranjujte v hladilniku (2 °C – 8 °C).
Store your Byetta pen properly. (See Storing Your Byetta Pen in Section 1 of this user manual for more information.)
Ustrezno shranjujte vaš injekcijski peresnik Byetta. (Za več informacij glejte Shranjevanje vašega injekcijskega peresnika Byetta v Poglavju 1 tega Priročnika za uporabo.)
Store your insulin inhaler in a dry place at room temperature.
Insulinski inhalator shranjujte na suhem pri sobni temperaturi.
Store your pen in the refrigerator.
Svoj peresnik shranjujte v hladilniku.
Store your pen with the pen cap on.
Peresnik shranjujte z nameščenim pokrovčkom peresnika.
Store your syringe in the refrigerator.
Svojo injekcijsko brizgo shranjujte v hladilniku.
Store your unused Lyxumia pens in the refrigerator, 2°C to 8°C.
Neuporabljene peresnike Lyxumia shranjujte v hladilniku pri temperaturi od 2 do 8°C.
Store your unused Lyxumia pens in the refrigerator, 2°C to 8°C.
Neuporabljene peresnike Lyxumia shranjujte v hladilniku pri temperaturi od 2°C do 8°C.
Stored applicators must be kept in the intact blister package.
Shranjene aplikatorje shranjujte v nepoškodovanih omotih.
STORED OUT OF THE REACH AND SIGHT OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
STORED OUT OF THE SIGHT AND REACH OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
STORED OUT OF THE SIGHT AND REACH OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
STORING AGENERASE
SHRANJEVANJE ZDRAVILA AGENERASE
Storing FORCALTONIN
Shranjevanje FORCALTONINA
Storing HEXAVAC
Shranjevanje HEXAVAC-a
STORING HEXAVAC
SHRANJEVANJE HEXAVACA
STORING PROCOMVAX
SHRANJEVANJE ZDRAVILA PROCOMVAX
Storing Quintanrix
Shranjevanje cepiva Quintanrix
Strain specific anti-HA antibody
Protitelo proti HA, specifično za sev
Strain-specific
2011-2012
Straining (5-point ordinal scale)
Napor (5- točkovna običajna lestvica)
Strains 2015/2016
Sevi 2016/2017
Strains Age range
Sevi Starostni razpon
Strains of inactivated Influenza A virus/swine (H3N2) ≥ 10.53 log2 GMNU, (H1N1) ≥ 10.22 log2 GMNU, (H1N2) ≥ 12.34 log2 GMNU
Sevi inaktiviranega virusa Influenca A /prašiči (H3N2) ≥ 10.53 log2 GMNU, (H1N1) ≥ 10.22 log2 GMNU, (H1N2) ≥ 12.34 log2 GMNU
strains of inactivated Influenza A virus/swine *
seve inaktiviranega virusa Influenca A/prašiči
Strains of inactivated Influenza A virus/swine/
Sevi inaktiviranega virusa Influence A /prašiči/
Strains of inactivated Influenza A virus/swine/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU*
Sevi inaktiviranega virusa Influenca A /prašiči/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU,
Strains of inactivated Influenza A virus/swine/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU,
Sevi inaktiviranega virusa Influenca A /prašiči/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU,
Strains of inactivated Influenza A virus/swine/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU1
Sevi inaktiviranega virusa Influenca A /prašiči/ Bakum/IDT1769/2003 (H3N2) ≥ 10.53 log2 GMNU1
Strains with P[4] genotype
Sevi z genotipom P[4]
Strains with P[6] genotype
Sevi z genotipom P[6]
Strains with P[8]
Krožeči sevi rotavirusov
Strains with P[8] genotype
Sevi s P[8] genotipom
Strains with P[8] genotype
Sevi z genotipom P[8]
Strains with P[8] genotype
Sevi z genotipomP[8]
strains): at least 2.0 ELISA U per
testu ELISA na odmerek
strains): at least 2.0 ELISA U per
≥ 2,0 enot v testu ELISA na odmerke
Strange taste in the mouth
čuden okus v ustih,
Strategies to prevent and treat hand-foot syndrome include:
Načini za preprečevanje in zdravljenje sindroma dlani in stopal :
Stratification: Randomisation was stratified by the intended use of ENF in the BR, previous use of darunavir and screening viral load.
Stratifikacija: randomizacija je bila stratificirana po namenih uporabe ENF v BR, po predhodni uporabi darunavirja in po virusnem bremenu ob presejalnem testiranju.
Stratified CMH p-value
p vrednost za stratificiran test CMH
Stratified CMH p-value
p-vrednost stratificiranega testa CMH
Stratified Cochran-Mantel-Haenszel test p-value
Vrednost p za stratificirani Cochran-Mantel- Haenszelov test
Stratified hazard ratio (95% CI)
Stratificirano razmerje ogroženosti (95 % IZ)
Stratified Hazard ratio b
Stratificirano razmerje ogroženosti b
Stratified log rank test
Stratificirani log-rang test
Stratified log-rank p-value
p vrednost za stratificiran test log-rank
Stratified log-rank p-value
p-vrednost stratificiranega testa log-rank
Stratified Log-Rank P-Value
vrednost P stratificiranega testa log-rank
Stratified Log-Rank Test p-value*
Vrednost p iz stratificiranega log-rang testa
Stratified Log-Rank Test p-value**
Vrednost p iz stratificiranega log-rang testa
Strawberry flavour (contains propylene glycol)
Aroma jagode (vsebuje propilenglikol)
Strength
EU/1/01/175/001
Strength
EU/1/07/431/057
Strength
EU/1/08/504/001
Strength
EU/1/09/521/001
Strength
EU/1/09/586/001
Strength
EU/1/09/593/001
Strength
EU/1/09/594/001
Strength
EU/1/10/631/001
Strength
EU/1/15/1051/001
Strength
EU/1/16/1108/002
Strength
Fertavid
Strength
IME ZDRAVILA
Strength
injiciranje
Strength
Izmišljeno Jakost
Strength
Izmišljeno Jakost ime
Strength
Jakosti
Strength
Moč
Strength
Velikost pakiranja
Strength
Zaščiteno
Strength
zdravila
Strength 2.5 mg:
Jakost 2,5 mg
Strength and number of pipettes to be administered
Jakost in število merilnih kapalk, ki jih je treba dati
Strength and number of tablets to be administered
Jakost in število odmerjenih tablet
Strength and number of tablets to be administered:
Jakost in število tablet v odmerku:
Strength and number of tablets to be administered:
Jakost in število tablet, ki jih damo psu:
Strength Pharmaceutical
jakost farmacevtska oblika
Strengths
Jakost
Strengths 5 mg, 7.5 mg and 10 mg:
Jakosti 5 mg, 7,5 mg in 10 mg
Strensiq 100 mg/ml solution for injection
Strensiq 100 mg/ml raztopina za injiciranje
Strensiq 100 mg/ml solution for injection (80 mg/0.8 ml)
Strensiq 100 mg/ml raztopina za injiciranje (80 mg/0,8 ml)
Strensiq 100 mg/ml solution for injection asfotase alfa
Strensiq 100 mg/ml raztopina za injiciranje asfotaza alfa
Strensiq 100 mg/ml solution for injection EU/1/15/1015/003
Strensiq 100 mg/ml raztopina za injiciranje EU/1/15/1015/003
Strensiq 100 mg/ml solution for injection Filled volumes of the vials are: 0.8 ml
Strensiq 100 mg/ml raztopina za injiciranje Napolnjeni volumni vial so: 0,8 ml
Strensiq 40 mg/ml solution for injection
Strensiq 40 mg/ml raztopina za injiciranje
Strensiq 40 mg/ml solution for injection asfotase alfa
Strensiq 40 mg/ml raztopina za injiciranje asfotaza alfa
Strensiq 40 mg/ml solution for injection EU/1/15/1015/001
Strensiq 40 mg/ml raztopina za injiciranje EU/1/15/1015/001
Strensiq 40 mg/ml solution for injection Strensiq 100 mg/ml solution for injection
Strensiq 40 mg/ml raztopina za injiciranje Strensiq 100 mg/ml raztopina za injiciranje
Strensiq can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing metabolic or bone disorders.
Zdravilo Strensiq se izdaja le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem presnovnih in kostnih bolezni.
Strensiq contains the active substance asfotase alfa.
Zdravilo Strensiq vsebuje zdravilno učinkovino asfotaza alfa.
Strensiq has been authorised under ‘exceptional circumstances’.
Zdravilo Strensiq je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
Strensiq has been studied in one main study in 13 children between 6 and 12 years of age.
Zdravilo Strensiq so proučevali v eni glavni študiji, ki je vključila 13 otrok, starih od 6 do 12 let.
Strensiq has no or negligible influence on the ability to drive and use machines.
Zdravilo Strensiq nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Strensiq has shown benefits for patients’ mineralization of the skeleton and growth.
Pokazalo se je, da zdravilo Strensiq bolnikom koristi pri mineralizaciji skeleta in rasti.
Strensiq is presented as a clear colourless to slightly yellow aqueous solution for injection in vials containing 0.3 ml, 0.45 ml, 0.7 ml and 1 ml of solution.
Zdravilo Strensiq je na voljo v obliki bistre in brezbarvne do rahlo rumenkaste vodne raztopine za injiciranje v vialah, ki vsebujejo 0,3 ml, 0,45 ml, 0,7 ml in 1 ml raztopine.
Strensiq is presented as a clear colourless to slightly yellow aqueous solution for injection in vials containing 0.8 ml of solution.
Zdravilo Strensiq je na voljo v obliki bistre in brezbarvne do rahlo rumenkaste vodne raztopine za injiciranje v vialah, ki vsebujejo po 0,8 ml raztopine.
Strensiq may cause allergic reactions in some people.
Zdravilo Strensiq lahko pri nekaterih ljudeh povzroči alergijske reakcije.
Strensiq should not be used during pregnancy or breast-feeding unless medically necessary.
Zdravila Strensiq ne smete uporabljati med nosečnostjo ali dojenjem, razen če je to potrebno zaradi zdravstvenih razlogov.
Streptococcus A,B,C,G: S ≤ 0.5 mg/L and R > 0.5 mg/L
Streptococcus A, B, C, G: S ≤ 0,5 mg/l in R > 0,5 mg/l
Streptococcus agalactiae,
Streptococcus pyogenes,
Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus)
Skupina Streptococcus anginosus (vključuje S. anginosus, S. intermedius in S. constellatus)
Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus)
Streptococcus anginosus group (vključuje S. anginosus, S. intermedius in S. constellatus)
Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus).
Streptococcus dysgalactiae, skupina Streptococcus anginosus (vključuje S. anginosus, S. intermedius in
Streptococcus anginosus group (including S. anginosus, S. intermedius and S. constellatus) Antibacterial activity against other relevant pathogens
Skupina Streptococcus anginosus (vključuje S. anginosus, S. intermedius in S. constellatus) Protibakterijska aktivnost proti drugim pomembnim patogenom
Streptococcus anginosus group* (includes S. anginosus, S. intermedius and S. constellatus) Streptococcus pyogenes*
Skupina Streptococcus anginosus* (vključuje S. anginosus, S. intermedius in S. constellatus) Streptococcus pyogenes
Streptococcus dysgalactiae,
Streptococcus agalactiae,
Streptococcus Groups A, B, C, G
Streptokoki skupine A, B, C, G
Streptococcus pneumoniae does not demonstrate cross-resistance between erythromycin A and telithromycin.
Streptococcus pneumoniae ne kaže navzkrižne odpornosti med eritromicinom A in telitromicinom.
Streptococcus pneumoniae: S ≤ 0.5 mg/L and R > 0.5 mg/L
Streptococcus pneumoniae: S ≤ 0,5 mg/l in R > 0,5 mg/l
Streptococcus pyogenes that show high-level resistance to erythromycin A are cross-resistant to telithromycin.
Streptococcus pyogenes, ki kažejo veliko odpornost proti eritromicinu A, so navzkrižno odporni proti telitromicinu.
Streptococcus pyogenes*
Inherentno odporni organizmi
Streptococcus pyogenes,
Staphylococcus aureus,
Streptococcus spp. other than S. pneumoniae S  0.25 mg/L and R  0.5 mg/L
Streptococcus spp., razen S. pneumoniae, S  0,25 mg/l in R > 0,5 mg/l
Streptococcus spp. other than S. pneumoniae S  1 mg/l and R > 1 mg/l
Streptococcus spp. z izjemo S. pneumoniae S  1 mg/l in R > 1 mg/l
Streptogramin
Zdravila po terapevtskih
Streptogramin antibiotics
treptogramini (sakvinavir/ritonavir)
Stretch
Razteg
Stretch
Raztegnite
Stretch marks
imeti brazgotin,
Stretch method
Način z raztezanjem
Stretch or pinch your injection site to create a firm surface.
Raztegnite ali stisnite mesto injiciranja, da boste ustvarili trdno površino.
Stretch technique
Način raztezanja
Stretch the skin on
Raztegnite kožo na
Stretching the skin creates a firm surface.
Z napenjanjem kože nastane ravna površina.
Stribild
Zdravilo Stribild
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Stribild 150 mg/150 mg/200 mg/245 mg filmsko obložene tablete elvitegravir/kobicistat/emtricitabin/dizoproksiltenofovirat
Stribild [Outer packaging only]
Stribild [samo na zunanji ovojnini]
Stribild can cause dizziness.
Zdravilo Stribild lahko povzroči omotičnost.
Stribild can only be obtained with a prescription and treatment should only be started by a doctor who is experienced in managing HIV infection.
Zdravilo Stribild se izdaja le na recept, zdravljenje pa sme uvesti samo zdravnik z izkušnjami pri zdravljenju okužbe z virusom HIV.
Stribild does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Stribild okužbe z virusom HIV-1 ali aidsa ne ozdravi, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Stribild has not been studied in patients over the age of 65.
Zdravila Stribild niso proučevali pri bolnikih, starejših od 65 let.
Stribild has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Zdravila Stribild niso preučili pri bolnikih s hudo jetrno okvaro (stopnje C po Child-Pughu).
Stribild is a single tablet regimen for the treatment of human immunodeficiency virus (HIV) infection in adults aged 18 years and over.
Zdravilo Stribild je režim ene same tablete za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti (HIV) pri odraslih, starih 18 let in več.
Stribild is an antiviral medicine that contains the active substances elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil.
Stribild je protivirusno zdravilo, ki vsebuje zdravilne učinkovine elvitegravir, kobicistat, emtricitabin in dizoproksiltenofovirat.
Stribild is not to be given with other antiretroviral agents.
Zdravila Stribild ni dovoljeno uporabljati z drugimi protiretrovirusnimi učinkovinami.